Health News: Key Pharmaceutical Developments and WHO Findings

The latest health news highlights include mixed results from Recursion Pharmaceuticals and Athira Pharma's drug trials, BioAge Labs' US IPO filing, WHO's findings on mobile phones and brain cancer, and Aspen Pharmacare's new ventures. Additionally, notable developments involve Vaxcyte's vaccine progress and Illumina's court victory over EU merger regulations.

In today's health news, Nvidia-backed Recursion Pharmaceuticals experienced a 14% drop in shares after mixed results from a mid-stage study on an experimental drug for a rare brain disorder. Similarly, Athira Pharma announced that its Alzheimer's drug, fosgonimeton, did not achieve the primary objective in a mid-to-late stage trial.

BioAge Labs, which partners with Eli Lilly for obesity therapy, has filed for an IPO in the US after raising $170 million. Meanwhile, a WHO-commissioned review definitively stated that there is no link between mobile phone usage and brain cancer, despite the rise in wireless technology use.

Aspen Pharmacare fell short of its profit targets but is optimistic about future earnings through GLP-1 drug contracts. The company is also in talks to manufacture mpox vaccines, addressing the recent outbreak in Africa.

A significant development in vaccine innovation saw Vaxcyte's shares rise over 40% after promising early data on its experimental pneumococcal vaccine. The US government, despite negotiating drug prices, will still pay substantially more compared to other high-income countries. Lastly, Illumina claimed a legal victory in the EU courts, impacting the bloc's merger authority.

(With inputs from agencies.)